vorasidenib
servier
['vorasidenib']
ingo mellinghoff presented vorasidenib - oral inhibitor of idh1 &amp; 2 in low grade gliomas pfs benefit in vorasidenib at 27.7 mth vs to 11.1 mth in placebo gp. time to next treatment also increased. new option for low grade gliomas w idh mutation! #asco2023 
Chief Medical Oncology, Dep Director, Chief Scientific Officer, Miami Cancer Institute-interests brain tumors & pt education @baptisthealthSF #tweets are my own